Organogenesis Holdings Inc Cash Flow Conversion Efficiency
Organogenesis Holdings Inc cash flow conversion efficiency. Based on the latest financial reports, Organogenesis Holdings Inc (ORGO) has a cash flow conversion efficiency ratio of 0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.08 Million) by net assets ($385.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Organogenesis Holdings Inc (ORGO) total market value for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Organogenesis Holdings Inc (2001–2024)
Cash flow conversion efficiency of Organogenesis Holdings Inc from 2001 to 2024. This chart illustrates how Organogenesis Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Organogenesis Holdings Inc stock quote for real-time trading data and today's change.
Organogenesis Holdings Inc Cash Flow Conversion Ratio Explained
Organogenesis Holdings Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Organogenesis Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Organogenesis Holdings Inc ranked by their cash flow conversion efficiency. Review ORGO free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CONDOR ENERGIES INC.
F:WQ6
|
0.162x |
|
Bhiraj Office Leasehold Real Estate Investment Trust
BK:BOFFICE
|
0.023x |
|
Dhampur Sugar Mills Limited
NSE:DHAMPURSUG
|
0.483x |
|
CF Acquisition VII Corp
NASDAQ:CFFS
|
N/A |
|
Apollo Food Holdings Bhd
KLSE:6432
|
0.007x |
|
Magyar Bancorp Inc
NASDAQ:MGYR
|
0.030x |
|
Chongkundang
KO:001630
|
0.008x |
|
The Platinum Group Public Company Limited
BK:PLAT
|
0.025x |
Annual Cash Flow Conversion Efficiency for Organogenesis Holdings Inc (2001–2024)
The table below shows the annual cash flow conversion efficiency of Organogenesis Holdings Inc from 2001 to 2024. Also see ORGO current and non-current assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $385.32 Million | $14.21 Million | 0.037x | -66.76% |
| 2023-12-31 | $278.66 Million | $30.92 Million | 0.111x | +18.57% |
| 2022-12-31 | $265.67 Million | $24.86 Million | 0.094x | -63.56% |
| 2021-12-31 | $241.34 Million | $61.98 Million | 0.257x | +566.27% |
| 2020-12-31 | $141.81 Million | $5.47 Million | 0.039x | +106.39% |
| 2019-12-31 | $55.58 Million | $-33.53 Million | -0.603x | +53.28% |
| 2018-12-31 | $47.04 Million | $-60.74 Million | -1.291x | -65496.73% |
| 2017-12-31 | $298.01 Million | $-586.60K | -0.002x | -5.07% |
| 2016-12-31 | $300.11 Million | $-562.23K | -0.002x | -100.00% |
| 2015-12-31 | $-162.00 | $-10.19 Million | 62919.753x | +9389980.80% |
| 2001-12-31 | $-2.08 Million | $-1.40 Million | 0.670x | -- |
About Organogenesis Holdings Inc
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barrier… Read more